| Title |
High-dose of Imatinib (STI571) vs. low-dose Imatinib in combination with cytostatics vs. reference-dose of Imatinib (SPIRIT-study) |
| Scientific Title |
A Phase III Prospective Randomized Comparison of Imatinib at a Dose of 400mg in Combination With Peg-Interferon-alpha2a (Peg-IFNa2a) or Cytarabine (Ara-C) Versus Imatinib at a Dose of 600mg Versus Imatinib a Dose of 400mg for Previously Untreated Chronic Myelogenous Leukemia (CML) in Chronic Phase |
| Short Title |
CML STI571 Spirit |
| Trialgroup |
NN |
| Type of Trial |
randomized, open-label |
| Disease |
Chronic myeloic leukemia(CML) Chronic Phase
|
| Age |
>= 18 years |
| Status |
Active |
| Start of Recruitment |
01.09.2003 |
| Contactperson |
General Contact Person
Guilhot, Dr. med., Francois
Tel: +33 (0)549 444201
Email: f.guilhot@chu-poitiers.fr
|
| Shortprotocol |
Shortprotocol |
created 